Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Errthing > Oral Boards > Flashcards

Oral Boards Flashcards

1
Q

GBM: RT fields and dose

A

CTV 46Gy - T2 + 2cm

CTV 60Gy - T1 post / cavity + 2cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

GBM: temozolomide dosing during/after RT

A

during RT: 75mg/m2 daily

after RT: 150-200mg/m2 days 1-5 on q28day cycle for 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

GBM: max dose constraints for chiasm, brainstem, optic nerves, retina, and lenses

A 
chiasm 55Gy
brainstem 60Gy
optic nerves 55Gy
retina 50Gy
lenses 7Gy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

GBM: follow up

A

MRI one month after RT then ever 3 months thereafter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

GBM: simulation

A

supine, mask, fuse preop and postop MRIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

GBM: RT options for elderly or poor KPS

A

Roa - 40Gy/15fxs, age > 60 and KPS > 50
Bauman - 30Gy/10fxs, age > 65 and KPS < 50
(French trial showed improved MS with RT compared to observation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

WHO 3 glioma: RT fields and dose

A

CTV 5940 - GTV/cavity + T2 flair + 2cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

WHO 3 glioma: chemotherapy

A

PCV: procarbazine, lomustine, vincristine

given either before or after course of RT, possibly omit if 1p 19q codeletion is present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

WHO 3 glioma: max dose constraints for chiasm, brainstem, optic nerves, retina, and lenses

A 
chiasm 55Gy
brainstem 60Gy
optic nerves 55Gy
retina 36Gy
lenses 5Gy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

WHO 3 glioma: follow up

A

MRI one month after RT then ever 3 months thereafter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

WHO 2 glioma: RT fields and dose

A

CTV 54Gy - GTV / T2 FLAIR + 2cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Anal T2N0: RT fields and dose

A

CTV 42 - primary site, mesorectum, presacral, inguinal, external iliac, internal iliac
CTV 50.4 - GTV + anal canal + 2.5cm
PTV - 1cm margin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Anal T3-4N0: RT fields and dose

A

CTV 45 - primary site, mesorectum, presacral, inguinal, external iliac, internal iliac
CTV 54 - GTV + anal canal + 2.5cm (consider 60Gy if T4)
PTV - 1cm margin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Anal N+: doses

A

45Gy to elective nodal regions
50.4Gy to nodal regions with nodes <3cm
54Gy to primary and nodal regions with nodes >3cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Anal: chemotherapy

A

two cycles at a 4 week interval:
5FU 1000mg/m2 daily x 4 days
mitomycin 10mg/m2 x 1 day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Anal: workup

A

H&P: LN eval, DRE, anal sphincter tone, sexual history, HIV, HPV, IBD history, Gyn exam

Labs: CBC, HIV if risk factors

Proctoscopy with bx. FNA of inguinal nodes. MRI or EUS.

CT/MRI of A/P. CXR or CT chest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Rectal: criteria for WLE

A

T1, <3 cm, <30% circumference, margins >3mm, within 8 cm of anal verge, grade 1-2, no LVSI/PNI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Rectal: RT fields and dose (T3-4 or N+)

A

CTV 45 - mesorectum, presacrals, internal iliacs, obturators

CTV 50.4 - tumor/mesorectum + 2cm sup/inf

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Rectal: 2D fields

A

AP: L5/S1 down to bottom of obturator foramen or 3 cm below tumor, whichever is more inferior (anal verge for tumors close to anal verge), lat 2 cm on pelvic brim

lat: want ant behind pubic symphysis and 3cm in front of sacral promontory, post 1cm behind sacrum

If T4 with anterior structure invasion - move ant border in front of sacrum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Rectal: chemotherapy

A

preop with concurrent capecitabine 825mg bid M-F

adjuvant treatment for T3/4 or N+ is FOLFOX x 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what are the components of FOLFOX

A

leucovorin (FOLinic acid)
5FU
Oxaliplatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what are the treatment options for early stage esophageal cancer (Tis, T1a, T1b, T2)?

A

Tis/T1a - endoscopic resection + ablation
T1b - esophagectomy
T2 - esophagectomy alone if noncervical, <2cm, well differentiated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

definition of anal margin

A

area below anal verge encompassing 6cm of skin around anus, consists of keratinizing epithelum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

definition of anal verge

A

area near end of anus where nonkeratinizing epithelium becomes keratinizing epithelium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

anal cancer target coverage

A

primary PTV: 90/100
nodal ptv: 85/100
max dose 115%

26
Q

anal cancer constraints for small bowel, bladder, and femoral heads

A

small bowel: V45 < 20cc, Dmax 50Gy
bladder: V50 < 5%
femoral heads: V44 < 5%

27
Q

rectal cancer constraints for small bowel, and bladder

A

small bowel: V45 < 35cc, Dmax 50Gy

bladder: mean < 40Gy

28
Q

rectal cancer pCR rate

A

15-20%

29
Q

treatment paradigm for T1-2 rectal cancer not meeting criteria for WLE

A 
surgical resection (APR/LAR with TME)
give adjuvant CRT for pT3-4 or N+
30
Q

concurrent chemo for esophageal cancer

A

weekly taxol 50 and carbo AUC 2

31
Q

esophageal cancer OAR constraints per RTOG 1010 (lung and heart)

A

lung V5 < 50, V20 < 25

heart V40 < 50, mean < 30

32
Q

what nodes are treated for T3N0 gastric cancer

A

perigastric nodes

33
Q

what nodes are treated for N+ gastric cancer arising from proximal 1/3 (cardia)?

A

perigastric, celiac/PA, splenic, suprapancreatic

34
Q

what nodes are treated for N+ gastric cancer arising from middle 1/3 (body)?

A

perigastric, celiac, splenic, suprapancreatic, pancreatoduodenal, porta hepatic

35
Q

what nodes are treated for N+ gastric cancer arising from the distal 1/3 (antrum/pylorus)?

A

perigastric, celiac, suprapancreatic, pancreatoduodenal, porta hepatic

36
Q

AP/PA field borders for gastric cancer

A

superior: top of T9
inferior: bottom of L3
left lateral: include two thirds of left hemidiaphragm
right lateral: 4cm lateral to vertebral bodies

37
Q

lateral field borders for gastric cancer (if using 4 field)

A

superior: top of T9
inferior: bottom of L3
anterior: abdominal wall
posterior: half of vertebral bodies

38
Q

concurrent chemo dose for adjuvant gastric cancer

A

capecitabine 825mg BID

39
Q

gastric cancer OAR constraints (small bowel, liver, kidney)

A

small bowel: max < 54Gy

liver: V30 < 60%
kidney: one kidney with V20 < 33%

40
Q

“three phase contrast narrative” for pancreatic cancer

A

Inject 120-150 mL contrast. Noncontrast phase: Will show calcifications that could otherwise be confused with contrast

1) Early arterial phase, 20 sec. Will show arterial anatomy
2) late arterial/early portal phase. Scan delay of 35-50 seconds. Optimal attenuation between enhancing parenchyma and tumor in this phase.
3) Late portal, venous phase: scan delay of 70-80 seconds. Shows lymph nodes, liver mets, peritoneal implants

41
Q

criteria for very low risk prostate cancer

A

GS 6 in 1-2 cores, <50% of core,

42
Q

contraindications to prostate brachy

A

AUA score > 12, size >60cc or <30cc, prior TURP, large median lobe, prior RT, inflammatory bowel disease

43
Q

prostate brachy dose, energy, half-life for I-125 and Pd-103

A

I-125: 144Gy, 0.028MeV, 60 days

Pd-103: 125Gy, 0.021MeV, 17 days

44
Q

dosimetric criteria for prostate brachy with modified peripheral loading (D90, V100, V150, V200, urethral Dmax, urethral Dmax, rectal D2cc)

A 
D90 > 90% (goal of 130%)
V100 > 98%
V150 < 40%
V200 < 10%
urethral Dmax < 120
rectal D2cc < 100%
45
Q

treatment options for stage I seminoma

A

OBSERVATION (preferred)
carbo AUC 7 x 1 cycle
RT

46
Q

stage I seminoma dose and field (if forced to treat)

A

20Gy/10fxs

superior: top of T12
inferior: bottom of L5
lateral: transverse processes

47
Q

management of stage IIA, IIB, and IIC seminoma

A

IIA - RT
IIB - cisplatin/etoposide x 4 cycles (preferred), RT also an option
IIIC - BEP chemotherapy, no RT

48
Q

stage IIA/B seminoma dose(s) and field

A

20Gy/10fxs with 10Gy boost to IIA nodes (<2cm) or 16Gy boost to IIB nodes (2-5cm)

field is modified dog leg

superior: top of T12
inferior: top of acetabulum

49
Q

seminoma kidney constraints

A

single kidney D50 < 8Gy

bilateral kidney mean dose < 9Gy

50
Q

criteria for bladder preservation

A

T2-T4a, no hydronephrosis, no extensive CIS, able to undergo maximal TURBT

51
Q

Sedlis criteria for postop cervix

A

need two:
LVSI
size > 4cm
stromal invasion > 2/3

52
Q

Peters criteria for postop cervix

A

positive nodes, positive margins, parametrial invasion

53
Q

components of radical hysterectomy

A

mobilization of ureters, bladder, and rectum , dissect parametria out to pelvic sidewall, remove upper half of vagina

54
Q

postop cervix dose and fields

A

45Gy/25fxs EBRT + vaginal cuff HDR 5Gy x 2 to surface

field: L4/5 to bottom of obturator foramen, 2cm on pelvic brim, anterior border in front of pubic symphysis, posterior covers entire sacrum

55
Q

definitive cervix dose and fields

A

45 Gy in 25 fx with 4-field, inf at least 3 cm below disease or upper 2/3 vag, as well as HDR with tandem and ovoids with a dose of 6 Gy x 5 (5x6 Gy for EQD2 of 84) = 80-90 Gy to Point A. Treatments delivered 1-2 times per week Rx to point A. Boost gross nodes to 60 Gy.

56
Q

definitive cervix whole pelvic fields

A

L4/L5 to bottom of obturator foramen or 3 cm from lowest vaginal involvment, 2 cm on pelvic brim, ant is in front of pubic symphysis, post covers whole sacrum with extra 1 cm to cover uterosacral ligaments

57
Q

definitive cervix fields for positive PA nodes

A

PA nodes: If node positive, include periaortic node chain up to T11/T12. In current 0724 protocol, if common iliac nodes are positive then PA nodes are treated up to L1/L2. If PA nodes are positive, treated up to T11/T12.

58
Q

tandem and ovoid OAR constraints for bladder, rectum, and sigmoid (45Gy/25 EBRT + 30Gy/5fx HDR)

A

bladder: 90Gy EQD2, 9Gy per fx
rectum: 75Gy EQD2, 6Gy per fx
sigmoid: 75Gy EQD2, 6Gy per fx

59
Q

inoperable endometrial cancer staging

A 
Stage IA <8 cm uterine cavity sound
Stage IB >8 cm
Stage II involves corpus and cervix
Stage III parametrium, vagina, adnexa
Stage IV
   A local structures
   B metastatic
60
Q

describe tandem and ovoid procedure

A

I would take the patient to the OR place them in the dorsal lithotomy position and administer general anesthesia. I’d perform and EUA to assess response. After prepping the patient with betadine, a gold seed would be placed at the anterior cervix. A foley catheter would then be inserted to drain the bladder and the foley bulb inflated with 7cc half saline half contrast. I would inject 200 mL of saline into the bladder and clamp the foley. The uterus would be sounded to assess distance to the fundus and flexion, and the appropriate tandem inserted with the largest ovoids that could be accommodated. Packing would be placed anteriorly and posteriorly to the device with gauze soaked with contrast and clindamycin ointment to pack away from the bladder and rectum. I would then take AP and lateral orthogonal films to ensure adequate positioning and packing.

Errthing (12 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions